SIEMENS DIGITAL INDUSTRIES SOFTWARE

Empowering emerging medical device manufacturers

Leveraging the digital infrastructure to align with best practices and accelerate growth

SMB MDD manufacturers

Now, small- to medium-sized businesses (SMB) in MDD are looking to create the same infrastructure to get their own innovation to market – rapidly, cost-efficiently and at high quality that achieves regulatory compliance. They are realizing the MOM foundation is not a nice-to-have, it is a must-have to compete in this complex industry.

Siemens has recognized this market need and has developed a solution that gives access to the SMB with a scope that meets their critical competitive requirements while reducing the cost and time for implementation and maintenance. The result is a solution that expedites the realization of digital manufacturing, while achieving significant near-term benefits.

SMB MDD manufacturers are proving the value of digital manufacturing. Some of the results from these manufacturers leveraging the Siemens solution – Opcenter™ EX MDD software – include:

• Reducing lead time across all products by 15 to 20 percent

• Reducing device history record (DHR) review time by 80 percent

• Reducing nonconformance reports (NCRs) by 80 percent

• Completely eliminating paper costs

• Taking only two months from project rollout to measured benefits

This eBook reviews the industry trends in MDD and the unique challenges facing SMB. The requirements for a digital infrastructure that addresses those challenges are detailed, and the Siemens solution developed according to those requirements is explained. Further, we highlight the results achieved by SMB manufacturers that adopted the Siemens solution.

Opcenter EX MDD is a part of the Xcelerator™ portfolio, the comprehensive and integrated portfolio of software and services from Siemens Digital Industries Software.

Whether an MDD manufacturer is a global leader or an emerging player, they operate within the same complex environment. They compete to get innovation to market as quickly as possible, with the race against time often an existential challenge for the emerging competitors. MDD manufacturers produce two things – the product and the device history record. Ideally, both must be perfect – perfect product quality, perfect compliance. Yet the trends that face all manufacturers in this segment work against achieving that perfect state.

As innovation and consumer demand pushes us toward mass customization, product complexity is increasing. For MDD products, technologies like the internet of things (IoT), wearables and connected devices are all increasing the complexity in the manufacturing process. As personalized medicine increases, so, too, does the potential impact on the production cycle, leading to concepts of lot size/batch size of one.

The are several implications for this growing product complexity. First, the connection between manufacturing production and product and process design must be strong. Not only do the capabilities of the shop floor need to adjust with the product requirements, but the design teams must understand the constraints of the production environment. As lot sizes decrease, changes to production lines must be done more rapidly. And all of this must be done while maintaining the highest product quality and the details of regulatory compliance.

With the COVID-19 pandemic disrupting global supply chains on a monumental scale, manufacturers have had to reconsider how they plan for and source raw materials and components. For MDD, sourcing requirements have always been significant, with regulatory and quality requirements weighing heavily on supplier selection and ongoing quality monitoring. With 3D printing options becoming more available, component material alternatives have become more significant.

The impact on the manufacturing process includes more complexity in tracking and tracing, as well as supply quality processes. In addition, the options for replacing traditionally sourced components with 3D printed components must be vetted with manufacturing constraints and product quality issues. The opportunity for 3D printing to impact personalized medical devices is also in play.

The regulatory environment for the MDD continues to be a significant constraint on innovation and speed to market. In the U.S., the FDA initiatives are shifting its focus to product quality rather than traditional compliance. The European Union (EU) Commission’s proposal for Medical Devices Regulations establishes a modernized and more robust legislative framework to ensure better production of public health and patent safety – presenting new challenges for operations in that geography.

Despite regulatory intentions, product recalls are still rising. With social media and consumer engagement, the repercussions of recalls will be increasingly damaging to medical device company brands. Quality inspections will become more difficult to manage, while manufacturers will need to collect data through the entire product lifecycle. Further, the emergence of value-based care will continue to put pressure on costs and production efficiency.